This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BG Medicine Announces Late-Breaker Oral Presentation Of New Data On The BGM Galectin-3(R) Test In Heart Failure

Stocks in this article: BGMD

WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced the presentation of new clinical research data on the BGM Galectin-3® test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal. Among the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy which demonstrated the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients diagnosed with a form of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). i Heart Failure with Preserved Ejection Fraction is the fastest growing type of clinical heart failure in the United States and Europe, disproportionately affecting women and accounting for one-third to one-half of all hospital admissions for heart failure. ii

The Aldo-DHF study findings were presented by Dr. Frank Edelmann of the Department of Cardiology and Pneumology and the German Center for Cardiovascular Research at the University of Göttingen. The title of Dr. Edelmann's late-breaking special sessions oral presentation was Galectin-3 Reflects Functional Capacity and Clinical Outcome in Heart Failure with Preserved Ejection Fraction (The Aldo-DHF Biomarker Substudy.)

"Galectin-3 has the potential to be a valuable test in clinical risk stratification for heart failure patients. In this study of 422 patients with diagnosed HFpEF, elevated galectin-3 levels, and particularly changes in galectin-3 over time, were statistically predictive of subsequent hospitalizations and mortality," commented Dr. Edelmann.

"The data presented at ESC-HF further demonstrate that galectin-3 may be an important determinant of heart failure risk across the clinical spectrum of disease," stated Paul Sohmer, President and CEO of BG Medicine. "Unplanned hospitalizations of patients with heart failure are a major cost burden on healthcare systems, particularly among patients with a diagnosis of HFpEF, one of the fastest growing but most difficult types of heart failure to identify and treat. The data presented at ESC-HF suggest that galectin-3 testing may help to identify HFpEF patients who are at risk of near-term adverse events."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs